MoonLake Immunotherapeutics (MLTX)
12.51
-0.67
(-5.08%)
USD |
NASDAQ |
Sep 11, 16:00
12.59
+0.08
(+0.64%)
After-Hours: 20:00
MoonLake Immunotherapeutics Enterprise Value : 610.42M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 610.42M |
| September 10, 2026 | 666.44M |
| September 09, 2026 | 711.59M |
| September 08, 2026 | 813.59M |
| September 04, 2026 | 819.44M |
| September 03, 2026 | 834.49M |
| September 02, 2026 | 823.62M |
| September 01, 2026 | 829.47M |
| August 31, 2026 | 822.78M |
| August 28, 2026 | 817.77M |
| August 27, 2026 | 862.91M |
| August 26, 2026 | 870.44M |
| August 25, 2026 | 865.42M |
| August 24, 2026 | 849.54M |
| August 21, 2026 | 882.14M |
| August 20, 2026 | 891.34M |
| August 19, 2026 | 964.08M |
| August 18, 2026 | 930.64M |
| August 17, 2026 | 931.47M |
| August 14, 2026 | 941.50M |
| August 13, 2026 | 944.01M |
| August 12, 2026 | 1.005B |
| August 11, 2026 | 951.54M |
| August 10, 2026 | 1.013B |
| August 07, 2026 | 1.091B |
| Date | Value |
|---|---|
| August 06, 2026 | 1.072B |
| August 05, 2026 | 1.032B |
| August 04, 2026 | 1.064B |
| August 03, 2026 | 1.019B |
| July 31, 2026 | 1.106B |
| July 30, 2026 | 1.152B |
| July 29, 2026 | 1.101B |
| July 28, 2026 | 1.129B |
| July 27, 2026 | 1.227B |
| July 24, 2026 | 1.155B |
| July 23, 2026 | 1.183B |
| July 22, 2026 | 1.148B |
| July 21, 2026 | 1.242B |
| July 20, 2026 | 1.157B |
| July 17, 2026 | 1.210B |
| July 16, 2026 | 1.154B |
| July 15, 2026 | 1.233B |
| July 14, 2026 | 1.197B |
| July 13, 2026 | 1.271B |
| July 10, 2026 | 1.267B |
| July 09, 2026 | 1.231B |
| July 08, 2026 | 1.159B |
| July 07, 2026 | 1.166B |
| July 06, 2026 | 1.143B |
| July 02, 2026 | 1.149B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 32.89B |
| AC Immune SA | 163.10M |
| CRISPR Therapeutics AG | 3.418B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.80M |
| Total Expenses (Quarterly) | 61.80M |
| EPS Diluted (Quarterly) | -0.8362 |
| Earnings Yield | -30.66% |
| Normalized Earnings Yield | -30.66 |